Press Release
02 Nov, 2020
Beijing, Nov. 2, 2020——InnoCare Pharma (HKEX: 09969), a clinical-stage biopharmaceutical company, announced today the Investigational New Drug (IND) clearance of its Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib by the US Food and Drug Administration (FDA) for starting phase II clinical investigations in multiple sclerosis (MS) in the United States.
12 Oct, 2020
Beijing, Oct. 12, 2020——InnoCare Pharma (HKEX: 09969), a clinical stage biopharmaceutical company, announced today that the Company has appointed Dr. Manish Tandon as Vice President of Business Development, reporting to the Co-founder, Chairman and CEO, Dr. Jasmine Cui. Dr. Tandon will be responsible for the Company’s business development strategy and execution, external collaborations, licensing and M&A.
16 Sep, 2020
Beijing, Sept. 16, 2020——InnoCare Pharmaceuticals, a clinical stage biopharmaceutical company committed to discovering, developing, and commercializing innovative medicines for the treatment of cancer and autoimmune diseases, announced today that the company will present at the upcoming Morgan Stanley 2020 Virtual Asia Pacific Conference and ZGC Forum.
02 Jul, 2020
InnoCare Pharmaceuticals (HKEX: 09969), after successfully dosing the first patient in a Phase 2 trial of ICP-192 for urothelial cancer, today announced the first patient dosed in a Phase 2 clinical trial of ICP-192 in patients with cholangiocarcinoma.
28 Jun, 2020
InnoCare Pharmaceuticals (HKEX: 09969), a leader in the fields of cancer and autoimmune diseases, today announced the first patient dosed in a Phase 2 clinical trial of ICP-192 in patients with urothelial cancer.
28 Apr, 2020
On June 28, 2020, InnoCare (Stock Code:09969-HK), a leading innovator for global biopharmaceutical drugs, is proud to announce the appointment of Mr. Xiaodong Jin as Chief Commercial Officer (CCO).
24 Apr, 2020
On April 24th of 2019, InnoCare announced the approval of their proprietary pan-FGFR inhibitor ICP-192 by the US Food and Drug Administration (FDA) for initiation of clinical investigations. ICP-192 is the second innovative drug candidate from InnoCare approved for initiation of clinical trials in the US. ICP-192 is a highly selective pan-FGFR inhibitor targeting multiple solid tumors with FGFR gene aberrations. Currently phase I/II studies are underway in China, with encouraging preliminary results on safety and tolerability. Following the IND approval, InnoCare will soon initiate clinical studies in the US for ICP-192. InnoCare will also actively explore collaboration opportunities with innovative biotech and pharmaceutical companies in these areas. “In less than one year, another innovative drug candidate from InnoCare has obtained the FDA approval for initiation of clinical investigation. This further demonstrates the profound innovation capability of InnoCare. We will continuously focus our effort on discovering and developing safe and effective therapies for the benefit of patients around the world. " Said Dr. Jasmine Cui, co-founder, Chairman, and CEO of InnoCare.
23 Mar, 2020
On March 23, 2020, InnoCare (Hong Kong Stock Exchange Code: 09969) was officially listed on the main board of The Stock Exchange of Hong Kong Limited (Hong Kong Stock Exchange). InnoCare issued 250, 324,000 shares worldwide at HK $ 8.95 per share, raising approximately HK $ 2.24 billion. The company intends to use raised proceeds primarily for the company's core drug candidates, clinical development of other drug candidates in the pipeline, marketing authorization and external introduction of new projects, etc., and begin the commercialization process and layout of products. InnoCare focuses on two major therapeutic areas, cancers and autoimmune diseases, that have significant market opportunities and synergistic benefits. In less than five years, guided by the global vision of the management team, Innocare has achieved many great milestones, including the discovery and development nine Drug candidates, the submission of 2 NDA applications for core drug candidate ,Orelabrutinib (ICP-022), progressing the second and third drug candidates through Phase I / II clinical trials, and the IND application submission for the fourth drug candidate. These drugs have the potential to meet the huge, unmet, medical needs and benefit patients worldwide. InnoCare has been favored by many well-known investment institutions in the several rounds of financing so far, with its core competitiveness in research and development, balanced drug pipelines, and excellent teams. InnoCare co-founder, chairman and CEO Dr. Cui Jisong said: "Listing on the Hong Kong Stock Exchange marks a new era for InnoCare! In January of this year (2020), InnoCare was happy to report that the NDA for Orelabrutinib was included in the priority review by the NMPA. We are also happy to report that the new indication for Orelabrutinib was also accepted by the NMPA earlier this month. InnoCare was listed on the Hong Kong Stock Exchange today is also the first IPO of a biopharmaceutical company on the HKEX in 2020. This not only reflect the strong cohesion and execution of our team, but also a powerful demonstration of InnoCare's strong commitments. We were honored and heartened to hear the listing bell. Thank you for your recognition, affirmation and support of InnoCare from all walks of life. Starting from this, we will continue to make great strides on the road of innovative research and development, and we are committed to developing and providing innovative therapies for patients around the world, providing growth opportunities for our employees, creating value for shareholders, and shouldering more social responsibilities! "